Free tool
FAERS Monitor: Orkambi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211358 or its brand name (Orkambi, Ivacaftor, Lumacaftor). Reports on generic versions are filed under their own applications.
Reports
8,538
Serious
5,384
63% of reports
Hospitalization
4,461
Death reported
158
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infective pulmonary exacerbation of cystic fibrosis1,462
- hospitalisation888
- dyspnoea559
- pulmonary function test decreased397
- cough395
- infection370
- chest discomfort344
- cystic fibrosis328
- pneumonia269
- malaise225
- nasopharyngitis202
- fatigue200
- diarrhoea195
- respiration abnormal191
- pyrexia187
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 613 |
| 2016 | 1,493 |
| 2017 | 1,499 |
| 2018 | 1,638 |
| 2019 | 1,989 |
| 2020 | 728 |
| 2021 | 169 |
| 2022 | 121 |
| 2023 | 120 |
| 2024 | 69 |
| 2025 | 47 |
| 2026 | 52 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,621 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 1,462 | 904.1 | 854.8 | 964,532 |
| pulmonary function test decreasedSignal | 397 | 245.6 | 222.0 | 87,733 |
| cystic fibrosisSignal | 328 | 155.1 | 139.0 | 47,103 |
| respiration abnormalSignal | 191 | 70.2 | 60.9 | 12,602 |
| hospitalisationSignal | 888 | 14.3 | 13.4 | 11,000 |
| chest discomfortSignal | 344 | 8.3 | 7.5 | 2,205 |
| infectionSignal | 370 | 6.3 | 5.7 | 1,656 |
| coughSignal | 395 | 3.5 | 3.2 | 702 |
| nasopharyngitisSignal | 202 | 2.7 | 2.4 | 216 |
| dyspnoeaSignal | 559 | 2.4 | 2.2 | 483 |
| pneumoniaSignal | 269 | 2.0 | 1.8 | 145 |
| pyrexia | 187 | 1.3 | 1.2 | 15 |
| malaise | 225 | 1.3 | 1.1 | 12 |
| diarrhoea | 195 | 0.7 | 0.6 | 17 |
| fatigue | 200 | 0.6 | 0.6 | 44 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.